Tamarind seed polysaccharide (TSP) is a neutral water-soluble galactoxyloglucan isolated from the seed kernel of Tamarindus indica with average molecular weight (Mw) 600–800 kDa. The high viscosity of TSP slows solubilisation, and the absence of charged substituent hinders the formation of electrostatic interactions with biomolecules. TSP was sulphated in a one-step process using dimethylformamide as a solvent, and sulphur trioxide-pyridine complex as a sulphating reagent. Studies of chemical structure, molecular weight distribution and viscosity were conducted to characterise the synthesised products. The sulphation degree was established by conductimetric titration; the sulphate group distribution was studied by NMR spectroscopy and liquid chromatography-mass spectrometry, and sulphated TSP oligomers were obtained by enzymatic degradation with cellulase and/or xyloglucanase. Sulphated products showed higher solubility than TSP, Mws in the range of 700–1000 kDa, a sulphation degree of two to four per subunit and pseudoplastic behaviour. A preliminary study of mucoadhesion revealed the unexpected interaction of S-TSP with mucin, providing a route by which sulphated TSP interactions with biomolecules may be influenced.
Background/Objectives: Dry eye disease (DED) is an ocular condition that significantly impairs quality of life. In mild cases, it is commonly treated with artificial tears (ATs), while more advanced cases are managed with immunomodulatory and anti-inflammatory drugs. The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of topical anti-inflammatory drugs, immunomodulatory drugs, AT, and their combination in adults with DED. Methods: The protocol was registered in the PROSPERO database (CRD420251245079). Intervention studies were searched in MEDLINE and Scopus databases. Random-effects meta-analyses were performed with the R software (version 4.5.2). Results: A total of 42 studies were included in the meta-analysis of efficacy and 46 in the analysis of safety. Overall, ATs and anti-inflammatory drugs did not produce significant improvements in clinical outcomes compared with controls. Immunomodulatory drugs showed variable results, with inconsistent efficacy and an increased risk of ocular adverse events (AEs). In contrast, combination therapy with ATs significantly improved clinical outcomes, including tear production (mean difference, MD, mm: 1.96, 95% CI [0.58–3.34] for anti-inflammatory drugs and 2.73, 95% CI [0.93; 4.52] for immunomodulatory drugs) and tear break-up time (MD, s: 1.43, 95% CI [0.81; 2.05] for anti-inflammatory drugs and 1.41, 95% CI [0.68; 2.13] for immunomodulatory drugs), without increasing the risk of AEs. Conclusions: Topical combination therapy with anti-inflammatory or immunomodulatory drugs and ATs appears to provide clinical improvements in tear function and patient-reported outcomes in DED, without additional safety concerns compared with ATs alone. These findings support combination treatment as a promising therapeutic strategy.